Brückner R, Rothmund M, Hinterberger R
Dtsch Med Wochenschr. 1984 Apr 6;109(14):523-6. doi: 10.1055/s-2008-1069226.
The course of 32 patients with liver metastases of colorectal carcinoma, treated with liver infusions (5-fluorouracil, 500 mg/m2, or floxuridine, 12 mg/m2 daily) was compared with that of 40 regularly examined but untreated patients (control group) in whom, at most three months after a previous negative examination, non-resectable bilateral metastases with initially less than 25% liver involvement had been found. The two groups were comparable with respect to onset pattern and volume of liver metastases. CEA values, ultrasound and computer tomography were obtained in both groups within three months. Mean survival time in the control group was 7.3 (4-14) months. In the treatment group the catheter had been placed either transvenously or transarterially. Mean survival time in this group is at present 17 (4-46) months, with a remission rate of 81%; 18 of the 32 patients are still alive. The high catheter complication rate with the external systems has recently been completely avoided by using implantable pump systems. Liver infusion treatment is judged to be a hopeful measure in liver metastases from colo-rectal carcinoma, with respect to survival time, tumour regression and quality of life.
对32例结直肠癌肝转移患者进行肝灌注治疗（5-氟尿嘧啶，500mg/m²，或氟尿苷，每日12mg/m²），并与40例定期检查但未接受治疗的患者（对照组）进行比较。在对照组中，在前次检查结果为阴性后最多三个月时，发现了不可切除的双侧转移灶，初始肝受累面积小于25%。两组在肝转移的发病模式和体积方面具有可比性。两组均在三个月内进行癌胚抗原（CEA）值检测、超声检查和计算机断层扫描。对照组的平均生存时间为7.3（4 - 14）个月。治疗组通过静脉或动脉放置导管。目前该组的平均生存时间为17（4 - 46）个月，缓解率为81%；32例患者中有18例仍存活。最近，通过使用植入式泵系统，已完全避免了外部系统较高的导管并发症发生率。就生存时间、肿瘤消退和生活质量而言，肝灌注治疗被认为是结直肠癌肝转移的一种有前景的治疗方法。
